Test ID: TAE
Therapeutic Antibody by Flow Cytometry
Secondary ID 
A test code used for billing and in test definitions created prior to November 2011
82977
NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.
Yes
Useful For Suggests clinical disorders or settings where the test may be helpful
Detecting cell surface antigens on malignant cells that are potential therapeutic antibody targets
Determining the eligibility of patients for monoclonal antibody therapies
Monitoring response to the therapeutic antibody
Reflex Tests Lists test(s) that may or may not be performed, at an additional charge, depending on the result and interpretation of the initial test(s)
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| 88465 | Flow Cytometry Interp, 2-8 Markers | No, (Bill Only) | No |
| 88466 | Flow Cytometry Interp, 9-15 Markers | No, (Bill Only) | No |
| 88467 | Flow Cytometry Interp,16 or greater | No, (Bill Only) | No |
Testing Algorithm Delineates situation(s) when tests are added to the initial order. This includes reflex and additional tests.
When a blood or bone marrow is ordered, a panel specific to desired antibody and a professional interpretation will always be charged. The panel will be charged based on number of makers tested (80997 for first marker, 81047 for each additional marker). The interpretation will be set based on markers tested in increments of 2 to 8, 9 to 15, or 16 and greater.
Method Name A short description of the method used to perform the test
Flow Cytometry
Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name
Therapeutic Antibody Evaluation
Aliases Lists additional common names for a test, as an aid in searching
Alemtuzumab (Campath) (CD52)
Campath-1H (CD52)
CD20
CD33
CD52
Epratuzumab (hLL2) (CD22)
Gemtuzumab (Mylotarg) (CD33)
hLL2 (Epratuzumab) (CD22)
Ibritumomab Tiuxetin (Zevalin) (CD20)
IDEC-Y2B (CD20)
Mylotarg (Gemtuzumab) (CD33)
Rituximab (Rituxan) (CD20)
Tositumomab (Bexxar) (CD20)
Campath-1H (CD52)
CD20
CD33
CD52
Epratuzumab (hLL2) (CD22)
Gemtuzumab (Mylotarg) (CD33)
hLL2 (Epratuzumab) (CD22)
Ibritumomab Tiuxetin (Zevalin) (CD20)
IDEC-Y2B (CD20)
Mylotarg (Gemtuzumab) (CD33)
Rituximab (Rituxan) (CD20)
Tositumomab (Bexxar) (CD20)
External
link
PDF
document
Excel
document
Word
document